Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.08 Billion TWD | -1.45% |
| 2022 | 2.11 Billion TWD | 9.43% |
| 2021 | 1.93 Billion TWD | 25.34% |
| 2020 | 1.54 Billion TWD | 33.45% |
| 2019 | 1.15 Billion TWD | 13.46% |
| 2018 | 1.01 Billion TWD | -12.74% |
| 2017 | 1.16 Billion TWD | -2.54% |
| 2016 | 1.19 Billion TWD | 3.14% |
| 2015 | 1.16 Billion TWD | 22.76% |
| 2014 | 946.7 Million TWD | -9.27% |
| 2013 | 1.04 Billion TWD | -21.52% |
| 2012 | 1.32 Billion TWD | 10.75% |
| 2011 | 1.2 Billion TWD | 0.28% |
| 2010 | 1.19 Billion TWD | 6.25% |
| 2009 | 1.12 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 251.71 Million TWD | -44.74% |
| 2024 Q2 | 461.15 Million TWD | 83.21% |
| 2023 Q1 | 765.44 Million TWD | 41.1% |
| 2023 Q4 | 455.48 Million TWD | 34.34% |
| 2023 Q2 | 526.44 Million TWD | -31.22% |
| 2023 FY | 2.08 Billion TWD | -1.45% |
| 2023 Q3 | 339.06 Million TWD | -35.59% |
| 2022 Q1 | 529.53 Million TWD | 4.31% |
| 2022 Q4 | 542.47 Million TWD | 16.48% |
| 2022 Q3 | 465.73 Million TWD | -19.62% |
| 2022 FY | 2.11 Billion TWD | 9.43% |
| 2022 Q2 | 579.4 Million TWD | 9.42% |
| 2021 Q2 | 499.83 Million TWD | 18.55% |
| 2021 Q3 | 505.59 Million TWD | 1.15% |
| 2021 FY | 1.93 Billion TWD | 25.34% |
| 2021 Q1 | 421.61 Million TWD | -24.66% |
| 2021 Q4 | 507.66 Million TWD | 0.41% |
| 2020 Q4 | 559.61 Million TWD | 96.62% |
| 2020 Q3 | 284.62 Million TWD | -27.38% |
| 2020 Q1 | 307.43 Million TWD | 11.34% |
| 2020 FY | 1.54 Billion TWD | 33.45% |
| 2020 Q2 | 391.91 Million TWD | 27.48% |
| 2019 Q4 | 276.13 Million TWD | 27.24% |
| 2019 FY | 1.15 Billion TWD | 13.46% |
| 2019 Q3 | 217.01 Million TWD | -32.15% |
| 2019 Q2 | 319.84 Million TWD | -6.93% |
| 2019 Q1 | 343.64 Million TWD | 48.01% |
| 2018 FY | 1.01 Billion TWD | -12.74% |
| 2018 Q3 | 178.23 Million TWD | -46.49% |
| 2018 Q2 | 333.07 Million TWD | 20.7% |
| 2018 Q1 | 275.96 Million TWD | -19.67% |
| 2018 Q4 | 232.17 Million TWD | 30.26% |
| 2017 Q1 | 272.23 Million TWD | -9.79% |
| 2017 Q3 | 360.1 Million TWD | 87.19% |
| 2017 Q2 | 192.37 Million TWD | -29.34% |
| 2017 Q4 | 343.54 Million TWD | -4.6% |
| 2017 FY | 1.16 Billion TWD | -2.54% |
| 2016 Q4 | 301.76 Million TWD | -9.58% |
| 2016 Q1 | 266.48 Million TWD | -25.29% |
| 2016 Q3 | 333.74 Million TWD | 12.5% |
| 2016 FY | 1.19 Billion TWD | 3.14% |
| 2016 Q2 | 296.67 Million TWD | 11.33% |
| 2015 Q3 | 265.42 Million TWD | -9.28% |
| 2015 FY | 1.16 Billion TWD | 22.76% |
| 2015 Q1 | 247.53 Million TWD | -15.35% |
| 2015 Q2 | 292.56 Million TWD | 18.19% |
| 2015 Q4 | 356.69 Million TWD | 34.39% |
| 2014 Q2 | 242.4 Million TWD | -2.73% |
| 2014 Q3 | 162.65 Million TWD | -32.9% |
| 2014 Q1 | 249.22 Million TWD | -7.26% |
| 2014 FY | 946.7 Million TWD | -9.27% |
| 2014 Q4 | 292.42 Million TWD | 79.79% |
| 2013 Q1 | 298.06 Million TWD | 7.52% |
| 2013 FY | 1.04 Billion TWD | -21.52% |
| 2013 Q3 | 204.62 Million TWD | -24.78% |
| 2013 Q4 | 268.73 Million TWD | 31.33% |
| 2013 Q2 | 272.05 Million TWD | -8.73% |
| 2012 Q2 | 455.86 Million TWD | 62.92% |
| 2012 FY | 1.32 Billion TWD | 10.75% |
| 2012 Q4 | 277.2 Million TWD | -12.47% |
| 2012 Q3 | 316.69 Million TWD | -30.53% |
| 2012 Q1 | 279.81 Million TWD | -12.92% |
| 2011 Q2 | 317.95 Million TWD | 23.84% |
| 2011 Q1 | 256.74 Million TWD | -14.48% |
| 2011 Q3 | 304.54 Million TWD | -4.22% |
| 2011 FY | 1.2 Billion TWD | 0.28% |
| 2011 Q4 | 321.33 Million TWD | 5.51% |
| 2010 Q1 | 279.97 Million TWD | 0.0% |
| 2010 FY | 1.19 Billion TWD | 6.25% |
| 2010 Q2 | 307.05 Million TWD | 9.67% |
| 2010 Q4 | 300.21 Million TWD | -3.16% |
| 2010 Q3 | 310 Million TWD | 0.96% |
| 2009 FY | 1.12 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Apex Biotechnology Corp. | 1.67 Billion TWD | -24.449% |
| Sinphar Pharmaceutical Co.,Ltd. | 2.96 Billion TWD | 29.582% |
| Panion & Bf Biotech Inc. | 1.88 Billion TWD | -10.87% |
| GenMont Biotech Incorporation | 318.01 Million TWD | -556.083% |
| Abnova (Taiwan) Corporation | 382.05 Million TWD | -446.114% |
| Adimmune Corporation | 1.78 Billion TWD | -16.881% |
| Tanvex BioPharma, Inc. | 61.41 Million TWD | -3297.504% |
| Polaris Group | 7.48 Million TWD | -27789.868% |
| Energenesis Biomedical CO.,LTD. | 7.15 Million TWD | -29048.379% |
| UnicoCell Biomed Co., Ltd. | 24.58 Million TWD | -8385.262% |
| PELL Bio-Med Technology Co. Ltd. | 18.03 Million TWD | -11470.127% |